- Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Eledon Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2023$2.77 (-2.81%)Earnings
- Q4 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptMar 30, 2023$2.51 (+5.91%)Earnings
- Eledon Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 15, 2023
- Q3 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptNov 14, 2022$2.74 (+8.30%)Earnings
- Eledon Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference TranscriptSep 29, 2022
- Eledon Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Eledon Pharmaceuticals Inc at Gilmartin Group Inaugural Emerging Growth Company Showcase (Virtual) TranscriptAug 31, 2022
- Q2 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2022$3.47 (+2.36%)Earnings
- Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Q1 2022 Eledon Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2022$2.41 (+3.02%)Earnings
- Eledon Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 21, 2022
- Q4 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptMar 24, 2022$3.75 (-1.06%)Earnings
- Q3 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptNov 11, 2021$4.95 (+0.61%)Earnings
- Q2 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptAug 12, 2021$6.3 (-2.63%)Earnings
- Q1 2021 Eledon Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2021$8.8 (-5.38%)Earnings
- Eledon Pharmaceuticals Inc at NobleCon Investor Conference (Virtual) TranscriptJan 20, 2021
Eledon Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Good morning. Thank you all for coming today. My name is Steven Perrin. I'm the President and Chief Scientific Officer at Eledon Pharmaceuticals. I'm also the original founder of the molecule that we used to call AT-1501, and is now called tegoprubart.
Eledon Pharmaceuticals is a publicly traded biotech company, and we're focusing on multiple indications targeting CD40 ligand, which is a receptor expressed on immune cells. And we have multiple Phase 2 studies going in ALS and neurodegeneration, organ transplant, including kidney transplant as well as cellular transplant with islet cell transplant for Type 1 diabetes. And we're also in autoimmunity in an indication in the autoimmune nephritis called IgA nephropathy.
We have near-term milestones with all four trials reading out by the end of the year, with the first one reading out in ALS in late Q2. And IgA nephropathy, renal transplant, and islet cell transplant, we'll be presenting data at the end of the year. We have a strong financial profile right
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)